Sobi’s Elocta Receives Swiss Orphan Drug Designation for Haemophilia A

Swedish Orphan Biovitrum (Sobi) have announced that their haemophilia drug, Elocta, has secured orphan drug designation in Switzerland. Elocta (rFVIIIFc) is a long-acting recombinant factor VIII Fc fusion protein product candidate to treat patients with haemophilia A. Haemophilia is an inherited condition that affects the blood’s ability to clot. The most common type of haemophilia

Continue Reading